Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748950 | 1.00 | MEN1 (0.50) | MEN1KMT2APOLBLMNATSHR | |
| SCHEMBL5747491 | 0.87 | POLB (0.50) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL3857038 | 0.87 | POLB (0.50) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL3866714 | 0.85 | USP30 (0.54) | KMT2APOLBLMNATSHRSMN1; SMN2 | |
| SCHEMBL5747603 | 0.83 | KDM4E (0.53) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL3863212 | 0.83 | KDM4E (0.53) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL5745163 | 0.81 | PRKAA2 (0.49) | POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL3860102 | 0.81 | PRKAA2 (0.49) | POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL3862880 | 0.81 | ALDH1A1 (0.53) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL5746938 | 0.81 | ALDH1A1 (0.53) | MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | claimed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | claimed |
| EP-1680415-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2005035524-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENSIS INHIBITORS | ABBOTT LABORATORIES (US) | 2005-04-21 | — | — | WO | claimed |
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680415-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005035524-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENSIS INHIBITORS | ABBOTT LABORATORIES (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | FLT4, FLT1, KDR | MEN1 4169/4885KMT2A 4101/4885POLB 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.